Study of CP-751,871 in Combination With Carboplatin and Paclitaxel in Advanced Lung Cancer

Phase 1 Completed 19 enrolled Pfizer

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Investigate safety, tolerability and pharmacokinetics of CP-751,871 when given in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer

Timeline

Start: 2008-01
Primary completion: 2009-05
Completion: 2009-05

Publications

Goto Y, Sekine I, Tanioka M, Shibata T, Tanai C, Asahina H, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Kikkawa H, Ohki E, Tamura T. Figitumumab combined with carboplatin and paclitaxel in treatment-naive Japanese patients with advanced non-small cell lung cancer. Invest New Drugs. 2012 Aug;30(4):1548-56. doi: 10.1007/s10637-011-9715-4. Epub 2011 Jul 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Figitumumab	Monoclonal antibody	6 mg/kg	Intravenous
Subject	Figitumumab	Monoclonal antibody	10 mg/kg	Intravenous
Subject	Figitumumab	Monoclonal antibody	20 mg/kg	Intravenous
Background	Carboplatin	Small molecule	6 unknown	Intravenous
Background	Paclitaxel	Small molecule	200 mg/m2	Intravenous

Study of CP-751,871 in Combination With Carboplatin and Paclitaxel in Advanced Lung Cancer

Summary

Timeline

Publications

Drugs

Indications